FDA Approves New Acute Lymphoblastic Leukemia Treatment
The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Significant Portion of Pediatric NHL Cases Occur in Transplant Recipients
Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States.
ATO Consolidation in Pediatric APL Allows for Reduced Anthracycline Dose
Arsenic trioxide consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia and allowed for significant reductions in cumulative anthracycline doses.
CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.
FDA Approves Combination for Therapy-Related Acute Myeloid Leukemia
The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes.
Cancer Rates Raised in Patients With Primary Immunodeficiency Diseases
Patients with primary immunodeficiency diseases are at increased risk of certain cancers, according to a new study. The strongest association was with lymphoma.
FDA Approves New Targeted Agent for Acute Myeloid Leukemia
The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.
By clicking Accept, you agree to become a member of the UBM Medica Community.